Dr Sigurdur Kristinsson Talks iStopMM
Earlier this year, Dr Sigurdur Kristinsson from the University of Iceland visited the Binding Site head office in Birmingham, UK. He is leading the ground-breaking study, iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma), which will screen for monoclonal gammopathy of undetermined significance (MGUS) in all of the Icelandic population over 40 years of age.
Binding Site are proud to be performing the study’s initial screening phase, and will begin testing patients’ serum later this year. Screening involves a combination of serum protein electrophoresis, Freelite® and reflex serum immunofixation.
After touring the facilities and discussing the finer details of sample analysis, Dr Kristinsson kindly agreed to be interviewed by Dr Stephen Harding, Binding Site’s R&D Director. This interview is now available to view in full.
Dr Kristinsson discusses the progression from MGUS to symptomatic myeloma, and the impact of early treatment; one of the aims of this study is to assess the benefits of screening for MGUS. iStopMM will provide invaluable information about the ultimate causes of myeloma, and there are already plans to expand the initiative to other populations.
For the latest iStopMM news, please follow @BindingSiteHaem, @IMFmyeloma and @sykristinsson on Twitter.